Overview

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Status:
Completed
Trial end date:
2017-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
Phase:
Phase 3
Details
Lead Sponsor:
Sucampo AG
Sucampo Pharma Americas, LLC
Collaborators:
Sucampo AG
Sucampo Pharmaceuticals, Inc.
Takeda
Treatments:
Lubiprostone